Stay updated on Avapritinib vs Regorafenib in GIST Clinical Trial
Sign up to get notified when there's something new on the Avapritinib vs Regorafenib in GIST Clinical Trial page.

Latest updates to the Avapritinib vs Regorafenib in GIST Clinical Trial page
- Check4 days agoChange DetectedThe VOYAGER Phase 3 study record for avapritinib versus regorafenib in advanced GIST is displayed, with study details, results measures, eligibility information, and participating locations.SummaryDifference97%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe footer revision changes from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check25 days agoChange DetectedA notice announces NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs. The study page still displays a 403 error.SummaryDifference1%

- Check32 days agoChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check39 days agoChange DetectedThe site revision label changes from v3.7.0 to v3.7.1 while the page continues to display a 403 error.SummaryDifference0.2%

- Check53 days agoChange DetectedThe page now shows a 403 Forbidden error in place of the study details, blocking access to the study record and related information on the page. This reflects a permission or server error that prevents users from viewing study data or documents.SummaryDifference17%

Stay in the know with updates to Avapritinib vs Regorafenib in GIST Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Avapritinib vs Regorafenib in GIST Clinical Trial page.